A distinct set of PBM business practices have resulted in higher prices and delayed access to generics and biosimilars for patients, according to AAM CEO Dan Leonard.
The product is indicated as a complete regimen or in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients.
The medication is indicated for the induction of remission and for the treatment of adult patients with mildly to moderately active ulcerative colitis.
Although fludarabine phosphate for injection had a market value of roughly $4.9 million for the 12 months ending March 2022, the current market value is believed to be higher due to the recent market disruptions.